Background: Chronic Kidney Disease (CKD) is associated with an increased risk for stent thrombosis and adverse events following percutaneous coronary intervention (PCI). High platelet reactivity (HPR) is also an independent correlate of thrombotic events post PCI. Although CKD modulates platelet function, the impact of CKD on HPR remains controversial, and whether or not HPR confers a differential risk for MACE between CKD and non-CKD patients is unknown. Methods: We performed a post-hoc analysis of the ADAPT-DES registry, which included 8,583 patients (8,449 of whom had baseline serum creatinine measures) undergoing PCI with successful DES placement. All patients underwent platelet function testing using the VerifyNow assay. HPR was defined as platelet reactivity units (PRU) 208. CKD was defined as a creatinine clearance <60 mL/min. We compared the frequency and impact of HPR on MACE between CKD and non-CKD patients. Results: Patients with CKD (n¼1,395; 16.5%) were older and more often female and diabetic, and had a lower ejection fraction compared to their non-CKD counterparts (n¼7,054). Unadjusted HPR prevalence was higher among those with vs. without CKD (48.9% vs. 41.5%, P<0.001). However, after multivariable adjustment this association was attenuated and no longer significant. While 1-year MACE rates were higher among those with vs. without CKD (6.6% vs. 3.6%, P<0.001), the adverse and incremental impact of HPR on MACE was uniform across CKD strata (pint ¼ NS for all endpoints, Table 1 ). Conclusions: While HPR is more common among those with CKD, this association appears largely attributable to confounding risk factors that are more prevalent in these patients. The incremental impact of HPR on MACE is similar among those with and without CKD.
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Background: Chronic Kidney Disease (CKD) is associated with an increased risk for stent thrombosis and adverse events following percutaneous coronary intervention (PCI). High platelet reactivity (HPR) is also an independent correlate of thrombotic events post PCI. Although CKD modulates platelet function, the impact of CKD on HPR remains controversial, and whether or not HPR confers a differential risk for MACE between CKD and non-CKD patients is unknown. Methods: We performed a post-hoc analysis of the ADAPT-DES registry, which included 8,583 patients (8,449 of whom had baseline serum creatinine measures) undergoing PCI with successful DES placement. All patients underwent platelet function testing using the VerifyNow assay. HPR was defined as platelet reactivity units (PRU) 208. CKD was defined as a creatinine clearance <60 mL/min. We compared the frequency and impact of HPR on MACE between CKD and non-CKD patients. Results: Patients with CKD (n¼1,395; 16.5%) were older and more often female and diabetic, and had a lower ejection fraction compared to their non-CKD counterparts (n¼7,054). Unadjusted HPR prevalence was higher among those with vs. without CKD (48.9% vs. 41.5%, P<0.001). However, after multivariable adjustment this association was attenuated and no longer significant. While 1-year MACE rates were higher among those with vs. without CKD (6.6% vs. 3.6%, P<0.001), the adverse and incremental impact of HPR on MACE was uniform across CKD strata (pint ¼ NS for all endpoints, Table 1 ). Conclusions: While HPR is more common among those with CKD, this association appears largely attributable to confounding risk factors that are more prevalent in these patients. The incremental impact of HPR on MACE is similar among those with and without CKD. Background: Premature discontinuation of antiplatelet therapy after percutaneous coronary intervention is known to predict stent thrombosis (ST). We aimed to compare the impact of early versus late antiplatelet therapy discontinuation on ST in patients receiving first-and second-generation drug-eluting stents (DES). Methods: A total of 6587 patients undergoing PCI with DES were analyzed, of which 4580 received 1st-generation DES (Cypher or Taxus) and 2007 received 2nd-generation DES (Xience or Promus). Patients were categorized into timing of clopidogrel discontinuation within 1 year (never, <3 months, 3-12 months). The 1-year ARCdefined definite or probable ST was analyzed. Results: In patients with 1st-generation DES, 536 (11.7%) had clopidogrel discontinued, 173 (3.8%) within first 3 months and 363 (7.9%) at 3-12 months. Cumulative 1-year ST rates were 1.0%, 13.6%, 3.0% (p <0.001) for never, <3 months, 3-12 months discontinued, respectively. ( Figure A) In patients with 2nd-generation DES, 214 (11.9%) had clopidogrel discontinued, 94 (4.7%) within first 3 months and 120 (5.9%) at 3-12 months. Cumulative 1-year ST rates were 0.1%, 5.4%, 0% (p <0.001) for never, <3 months, 3-12 months discontinued, respectively. Background: While newer drug eluting stent (DES) promote more favorable vascular healing, the optimal duration of dual antiplatelet therapy (DAPT) after implantation with 2nd generation drug-eluting coronary stents remains undetermined. We aimed to test whether 6-month DAPT would be non-inferior clinical and angiographic outcome to 12-month DAPT after implantation of Zotarolimus-eluting stent (ZES) and biolimus-eluting stent (BES). Methods: This is a prospective, double-randomized, open-label, multicenter trial to compare clinical events between 6-month DAPT and 12-month DAPT (in a 1:1 ratio), and to demonstrate the non-inferiority of BES compared with ZES stents (in 1:1 ratio), angiographically. Currently, 1055 patients were randomly assigned. The primary end point was a major adverse cardiac events (MACE) at 12 months. Optical coherence tomography (OCT) at 6 month was performed in 30 patients of each group. The primary endpoint was MACE, secondary end points are target lesion failure, insegment LL at 12 months, and neointimal hyperplasia (NIH) by OCT at 6 month. 
